Related references
Note: Only part of the references are listed.Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy
Benjamin Hanfstein et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib
Thomas Ernst et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Sara Redaelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O'Hare et al.
BLOOD (2007)
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications
Ingo Roeder et al.
NATURE MEDICINE (2006)
Selecting and deselecting imatinib-resistant clones:: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL
FXE Gruber et al.
LEUKEMIA (2005)
Dynamics of chronic myeloid leukaemia
F Michor et al.
NATURE (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells
MC Müller et al.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2002)
Share Paper
